Alkermes PLC (NAS:ALKS)
$ 24.51 0.17 (0.7%) Market Cap: 4.15 Bil Enterprise Value: 3.74 Bil PE Ratio: 9.69 PB Ratio: 3.30 GF Score: 66/100

Alkermes Plc ARTISTRY-1 Data Call at ASCO Transcript

Jun 06, 2022 / 12:00PM GMT
Release Date Price: $26.35 (-3.31%)
Operator

Greetings. Welcome to the Alkermes Webcast with Expert Oncologist Panel to Discuss Nemvaleukin Alfa at ASCO 2022. My name is Rob, and I'll be your operator for today's call. (Operator Instructions) Please note, this conference is being recorded.

I'll now turn the call over to Sandra Coombs, Senior Vice President of Investor Relations and Corporate Affairs. Sandy, you may begin.

Sandra Coombs
Alkermes plc - SVP of Corporate Affairs & IR

Thank you so much. Good morning, and welcome to the Alkermes plc conference call and webcast to discuss clinical data from our ARTISTRY-1 trial that were included in an oral presentation at the 2022 American Society of Clinical Oncology Annual Meeting.

Please note that during today's call, we will reference slides that are available on the webcast. If you've not already done so, please go to the Investors section of our site, alkermes.com, to access the webcast player. A PDF of the slides will also be available on our website following the conclusion of the call.

During this presentation, we will

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot